Medtronic plc Q1 2027 Earnings Recap

Shares rose modestly by 1.7% following a solid quarter marked by strong revenue growth and continued share gains across key segments, though the market’s tepid response suggests investors remain cautious about near-term outlook or incremental upside.

Key Takeaways

• Revenue reached $9.8 billion with adjusted EPS of $1.45, both described as well ahead of expectations by management.
• Organic revenue grew 13.7%, driven by Cardiac Rhythm Management (CRM) (+15%), Cranial & Spinal Technologies (CST) (+13%), and Surgical (+9%).
• Cardiac Ablation Solutions delivered an 88% global growth, surpassing $2 billion in trailing 12-month revenue and expanding U.S. share by 9 points.
• Recent acquisitions contributed positively to reported growth and portfolio strength.
• Management emphasized durable, multi-platform growth and innovation pipelines, but the sub-3% stock rise suggests investors are withholding enthusiasm pending further clarity on outlook or execution risks.